Clinical Trials Sponsored by Context Therapeutics

Total 6439 results

Allogene Therapeutics

Active, not recruiting

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States
Celldex Therapeutics

Completed

A Study of CDX-0159 in Patients With Prurigo Nodularis

Prurigo Nodularis

United States, Germany, Poland
ConSynance Therapeutics

Completed

A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome

Prader-Willi Syndrome

United States
Aprea Therapeutics

Terminated

APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) (R/R)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States
Amicus Therapeutics

Available

Expanded Access for ATB200/AT2221 for the Treatment of IOPD

Pompe Disease Infantile-Onset

Taiwan, United States, Italy
Amicus Therapeutics

Available

Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease

Pompe Disease
Celldex Therapeutics

Completed

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

United States, Germany
Sage Therapeutics

Completed

A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting

Postpartum Depression

United States
Fulcrum Therapeutics

Active, not recruiting

Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension (FSHD)

Facioscapulohumeral Muscular Dystrophy 1

Netherlands
Karuna Therapeutics

Terminated

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia (PENNANT)

Schizophrenia

United States
Decibel Therapeutics

Completed

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

Ototoxicity

United States, Australia
Fate Therapeutics

Withdrawn

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Transformed Indolent Non-Hodgkin's Lymphoma
Tessa Therapeutics

Completed

A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (VANCE)

Nasopharyngeal Carcinoma

United States, Taiwan, Malaysia, Singapore, Thailand
Heron Therapeutics

Completed

Phase 2 Bunionectomy HTX-011 Administration Study

Postoperative Pain

United States
Lava Therapeutics

Active, not recruiting

Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Lymphocytic Leukemia

United States, Spain, France, Netherlands
Mana Therapeutics

Terminated

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT

AML/MDS

United States
Corcept Therapeutics

Completed

Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome (RE-KLAIM)

Cushing's Syndrome
Windtree Therapeutics

Terminated

A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age

Respiratory Distress Syndrome, Newborn

Poland
Fate Therapeutics

Completed

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions

United States
Aligos Therapeutics

Terminated

A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects

Chronic Hepatitis B

United Kingdom, New Zealand
Prelude Therapeutics

Completed

A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas

Advanced Solid Tumor | Recurrent Glioma

United States
Tessa Therapeutics

Active, not recruiting

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

Hodgkin Lymphoma, Adult | Hodgkin Disease Recurrent | Hodgkin Disease Refractory | Hodgkin Disease, Pediatric

United States
Faeth Therapeutics

Withdrawn

Medical Food for the Dietary Management of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Celldex Therapeutics

Terminated

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Advanced Head and Neck Squamous Cell Carcinoma

United States
Nocion Therapeutics

Completed

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

Refractory Chronic Cough

United States
Design Therapeutics

Completed

Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia

Friedreich Ataxia

United States
Prelude Therapeutics

Completed

A Study of PRT1419 in Patients With Advanced Solid Tumors

Melanoma | Sarcoma | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Esophageal Cancer | Lung Cancer

United States
Nektar Therapeutics

Terminated

Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors (PROPEL)

Non-Small Cell Lung Cancer

United States, Germany, Spain, Australia, France
Vaxiion Therapeutics

Completed

A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer

Urothelial Carcinoma of the Urinary Bladder

United States
Iterion Therapeutics

Completed

Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059

Desmoid Tumor

United States, Canada
Windtree Therapeutics

Completed

Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan

Hypertension

Taiwan
United Therapeutics

Terminated

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) (PERFECT)

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Israel, Argentina, Puerto Rico
Cartesian Therapeutics

Active, not recruiting

Descartes-11 in Multiple Myeloma

Multiple Myeloma

United States
Maze Therapeutics

Completed

A Randomized Phase 1 of of MZE001 in Healthy Volunteers

Healthy

United States
Amicus Therapeutics

Active, not recruiting

Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene Transfer

Batten Disease | CLN6

United States
TRYP Therapeutics

Active, not recruiting

Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder

Binge Eating Disorder

United States
Eleusis Therapeutics

Completed

A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers

Healthy

United Kingdom
Fulcrum Therapeutics

Completed

Safety, Tolerability and Pharmacokinetics of FTX-6058

Sickle Cell Disease | Healthy Adult Subjects

United States
Aerami Therapeutics

Completed

Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution

Pulmonary Arterial Hypertension

Australia
United Therapeutics

Terminated

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Pulmonary Hypertension | Interstitial Lung Disease | Combined Pulmonary Fibrosis and Emphysema

United States, Puerto Rico
Visus Therapeutics

Completed

Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

Presbyopia

United States
Summit Therapeutics

Completed

To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection (Ri-CoDIFy 2)

Clostridioides Difficile Infection

United States, Spain, France, Canada, Belgium, Israel, Chile, Belarus, Latvia, Germany, Romania, Lithuania, Mexico, Czechia, Estonia, Georgia, Peru
ProQR Therapeutics

Active, not recruiting

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, Netherlands, United Kingdom, Germany
Corcept Therapeutics

Terminated

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Heron Therapeutics

Terminated

Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)

COVID-19

United States
Fate Therapeutics

Terminated

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

Hematological Malignancy

United States
Sage Therapeutics

Terminated

A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)

COVID-19 | Acute Respiratory Distress Syndrome

United States
ASCEND Therapeutics

Completed

Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80

Hypogonadism | Low Testosterone | Late Onset Hypogonadism

United States
Centrexion Therapeutics

Completed

A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain

Osteoarthritis, Knee

United States
Aprea Therapeutics

Terminated

APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | MDS

United States

Clinical Trials Sponsored by Context Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations